PDCD1 and neoplasm: For the clinical study with immunotherapy, the literature indicated that nivolumab (anti-PD-1) has anti-tumor efficacy and safety in patients with GC, which is delivered as maintenance treatment (after the illness is under control with conventional chemotherapy) (72).